Topics

Participation in the 16th Annual Conference on Biomolecular Screenology – Exhibition Booth and Corporate Seminar

Conference Name:  the 16th Conference on Biomolecular Screenology

Axcelead will exhibit a corporate booth and host a seminar at the 16th Conference on Biomolecular Screenology, to be held in Tokyo from November 27, 2025. Please note that registration for participation and seminar applications has already closed (no on-site registration available).

Event Overview
Date: November 27 (Thu) – November 28 (Fri), 2025
※ Axcelead’s booth and seminar will be held on November 28 only
Venue: Tower Hall Funabori
Booth Number: #2-6 (2nd Floor, Heian & Zuiun Exhibition Hall)
Corporate Seminar: “An AI-Driven Efficient Lead Generation Platform” (4th Floor, Training Room)

About the Exhibition Booth
Axcelead is a drug discovery solution provider offering one-stop support services from target identification to IND filing, built upon decades of expertise, knowledge, and experience in pharmaceutical R&D. We provide a wide range of screening-related solutions, including high-quality hit identification through high-throughput screening using our proprietary compound library, as well as lead generation leveraging AI, medicinal chemistry, and other advanced capabilities. At our booth, Axcelead researchers will introduce services designed to address your challenges, including but not limited to:

  • AI-Driven Efficient Lead Generation Platform (Corporate Seminar)
  • Solutions for Novel Small-Molecule Modalities (Protein Degraders, RNA-Targeting Small Molecules)
  • High-Quality, Rapid, and Cost-Effective HT-ADMET Services
  • ADC-Related Services
  • Accelerated Lead Generation Using Axcelead’s Proprietary Data

We also welcome discussions on topics not listed above, including challenges beyond screening.

About the Corporate Seminar
In this seminar, we will present an overview of Axcelead’s hit identification platform, which boasts a high success rate, along with our “Lab-in-the-Loop” lead generation platform. This platform maximizes the use of AI-based predictive models to efficiently connect hit identification with lead optimization. This year’s seminar will focus on case studies of lead generation for challenging targets, providing more concrete examples of practical applications compared to last year’s seminar.

Speakers

Akito Hata, VP, Head of Screening Business Unit, Axcelead Drug Discovery Partners, Inc.

Akito Hata is a scientist specializing in early-stage drug discovery, with deep expertise in in vitro biology and high-throughput screening. He joined Axcelead Drug Discovery Partners, Inc. in 2021, where he played a key role in building the company’s kinase inhibitor and targeted protein degradation platforms. In 2023, he became the leader of the Protein Science team, and since January 2024 he has overseen the Screening Business Unit, driving its scientific direction and operational strategy.
Before joining Axcelead, Akito worked as a research scientist at Takeda Pharmaceuticals both in Japan and in Boston, gaining broad experience across early-stage small-molecule drug discovery programs in Japan as well as antibody and cell therapy projects in the US. His diverse background spans multiple modalities and discovery technologies, positioning him as a cross-functional leader in modern drug discovery.

Dr. Hiroshi Kajino is a researcher on machine learning and its application to chemistry. He obtained his Ph.D. degree in 2016 from the University of Tokyo on privacy-preserving techniques for machine learning, and since then he had been a research staff member at IBM Research – Tokyo until February 2024. During his tenure in IBM Research, not only has he regularly published research papers in top-tier conferences but also has contributed to business applications of machine learning to a wide variety of industry, including materials science. He also led several research projects in IBM Research including drug discovery. His current research interest is optimization of molecular structures using machine learning. He has published a one-of-a-kind monograph on the research topic.